Versuchen GOLD - Frei
Lactose India unveils new specialized grades
Chronicle Pharmabiz
|November 27, 2025
IN a significant boost to India’s pharmaceutical sector, Lactose India Ltd (LIL) has launched a new lineup of specialized lactose grades, marking a pivotal advancement in the country’s domestic production capabilities.
Established in 1991 and headquartered along the Vadodara-Ahmedabad Expressway in Poicha, LIL is leveraging its expansive state-of-the-art five-acre facility to deliver high-value high performance lactose products. This move not only expands their product portfolio but also aligns seamlessly with the national vision of “Atma Nirbhar Bharat” (Self-Reliant India) and “Make in India,” reducing the nation’s dependence on imports for critical pharmaceutical excipients.
In keeping with its commitment to responsible growth, Lactose India’s focus on sustainability drives operational excellence — through optimized energy-efficient processes, reduced emissions, conscious material sourcing, wastewater recycling systems to promote greener practices across its product lifecycle. Every batch reflects LIL’s holistic belief that progress and environmental governance must go hand in hand.
Lactose India, a recognized leader in lactose monohydrate production with an installed capacity of 12,000 metric tons per annum - is set to double following a recent acquisition - is a market leader for its regular grades such as 200 Mesh, 125M, 450M, PHA, DC2050, DC60, 80M, 100M, 325M, and IMP variants in milled and sieved forms. These have served both domestic and overseas markets effectively.
The introduction of specialized segments marks a strategic evolution, targeting niche applications in pharmaceuticals, including excipients, APIs, and formulations - all housed within a single campus featuring dedicated production blocks, warehouses, and quality assurance offices, ensuring world class standards in every batch.
New specialized grades: Innovation meets demand
Diese Geschichte stammt aus der November 27, 2025-Ausgabe von Chronicle Pharmabiz.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Chronicle Pharmabiz
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 mins
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 mins
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 mins
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 mins
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 mins
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 mins
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 mins
December 11, 2025
Listen
Translate
Change font size
